This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome (MATOCSS)

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Michael Wechsler, MD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT00527566
First received: September 7, 2007
Last updated: February 1, 2017
Last verified: February 2017
  Purpose
The purpose of this study is to determine whether Mepolizumab (a monoclonal antibody against interleukin-5) is a safe and well-tolerated therapy that will allow for steroid tapering in patients with steroid-dependent Churg-Strauss Syndrome (CSS).

Condition Intervention Phase
Churg Strauss Syndrome Biological: Mepolizumab Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Mepolizumab As a Steroid Sparing Treatment Option in the Churg Strauss Syndrome

Resource links provided by NLM:


Further study details as provided by Michael Wechsler, MD, Brigham and Women's Hospital:

Primary Outcome Measures:
  • Number of Participants With Indicated Side Effects [ Time Frame: Participants were followed for the duration of the study, approximately 44 weeks ]
    Side effects experienced by participants 1 to 2 days after Mepolizumab infusion.

  • Number of Participants Who Experienced Specific Symptoms [ Time Frame: 44 weeks ]
    Number of participants who experienced specific symptoms during the trial.


Secondary Outcome Measures:
  • Steroid Dosing During Trial [ Time Frame: 20 weeks ]
  • Evaluate Overall Positive Change in Churg-Strauss Syndrome Via the Measures Outlined in Study Aims [ Time Frame: 20 weeks ]
    The Asthma Control Questionnaire (ACQ) was one measure used to assess the prevalence of asthma symptoms the participant was having during the study. It is a series of 7 questions assessing how often, over the past two weeks, the participant wakes up from their asthma, how bad their symptoms were, etc. The greater the prevalence of symptoms, the higher the score. Each of the 7 questions is scored 0-6. The total score is calculated by adding the individual question scores and dividing the sum by 7.

  • Efficacy- Exacerbation Rate [ Time Frame: Treatment period (12 weeks) ]
    Quantified the exacerbation rate (total number of exacerbations per day) of the participants during treatment with mepolizumab and without treatment. Exacerbations were characterized as any worsening of clinical disease requiring an increase of systemic corticosteroid therapy (e.g. prednisone) for asthma, respiratory symptoms, or underlying vasculitis.


Enrollment: 10
Study Start Date: September 2007
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Mepolizumab
Subjects will receive open-label mepolizumab
Biological: Mepolizumab
IV mepolizumab, 750 mg
Other Name: Anti IL-5

Detailed Description:

Specific Aims:

  1. Document the safety of mepolizumab therapy in patients with CSS.
  2. Demonstrate the steroid sparing effect of mepolizumab therapy by decreasing corticosteroid dosage while using this anti-IL5 therapy.
  3. Demonstrate the efficacy of anti-IL5 therapy in improving the signs and symptoms of CSS by:

    1. Measuring serum markers of CSS disease activity, including: peripheral eosinophilia, erythrocyte sedimentation rate, anti- neutrophil cytoplasmic antigen, C-reactive protein and IgE levels.
    2. Assessing the activity level of vasculitis via the Birmingham Vasculitis Activity Score
    3. Evaluating asthmatic response via serial peak flow and FEV1 measurements as well as asthma symptom scores using the Juniper scale.
    4. Assessing changes in novel parameters such as fractional excretion of nitric oxide and IL-5 levels.
  Eligibility

Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age >18 years old
  • Diagnosis of Churg Strauss Syndrome
  • Maintained on stable corticosteroid dose of at least prednisone 10mg daily (or equivalent) prior to enrollment in study
  • If on cyclophosphamide, azathioprine or methotrexate, must be on a stable dose and be able to maintain that dose for the duration of the study

Exclusion Criteria:

  • Hypereosinophilic Syndrome
  • Wegener's Granulomatosis
  • Malignancy
  • Parasitic Disease
  • Pregnant or nursing
  • If female and of child-bearing potential, must have negative pregnancy test prior to each infusion of study medication and must adhere to acceptable method of contraception (with <1% failure rate)
  • Any other medical illness that precludes study involvement
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00527566

Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
GlaxoSmithKline
Investigators
Principal Investigator: Michael Wechsler, MD Brigham and Women's Hospital
  More Information

Publications:

Study Data/Documents: Publication  This link exits the ClinicalTrials.gov site
Identifier: PubMed ID: 20513524

Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.

Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. J Allergy Clin Immunol. 2010 Jun;125(6):1336-43. doi:10.1016/j.jaci.2010.03.028.



Responsible Party: Michael Wechsler, MD, Assistant Professor of Medicine at Harvard Medical School and Brigham and Women's Hospital, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT00527566     History of Changes
Other Study ID Numbers: 2007-P-000012/1;BWH
Study First Received: September 7, 2007
Results First Received: June 22, 2011
Last Updated: February 1, 2017

Keywords provided by Michael Wechsler, MD, Brigham and Women's Hospital:
Churg Strauss Syndrome

Additional relevant MeSH terms:
Syndrome
Churg-Strauss Syndrome
Disease
Pathologic Processes
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Systemic Vasculitis
Vasculitis
Vascular Diseases
Cardiovascular Diseases
Granuloma
Lymphoproliferative Disorders
Lymphatic Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on June 27, 2017